Table 2.
Univariable and multivariable analysis of factors associated with persistence of symptoms (between March 10 and July 3, 2020)a.
| Variables | n | Complete resolution at day 30 |
Univariable analysis |
Multivariable analysis |
|||
|---|---|---|---|---|---|---|---|
| No. (n = 175) | Yes (n = 254) | HR (95%CI) | P-value | HR (95%CI) | P-value | ||
| Age | 429 | 44.9 (34.2–52.7) | 37.2 (29.4–50.2) | 0.99 (0.98–0.99) | 0.0058 | ||
| ≤ 30 | 429 | 30 (28.0) | 77 (72.0) | 1 | 0.0007 | 1 | 0.0065 |
| [30; 40] | 33 (33.3) | 66 (66.7) | 0.82 (0.61–1.11) | 0.93 (0.62–1.40) | |||
| >40 | 112 (50.2) | 111 (49.8) | 0.62 (0.48–0.80) | 0.61 (0.44–0.86) | |||
| Gender | 429 | ||||||
| Male | 38 (32.2) | 80 (67.8) | 1 | 0.0036 | 1 | 0.0332 | |
| Female | 137 (44.0) | 174 (56.0) | 0.71 (0.56–0.89) | 0.70 (0.51–0.97) | |||
| Place of work | 428 | ||||||
| Healthcare facility | 150 (39.6) | 229 (60.4) | 1 | 0.941 | |||
| Non-healthcare facility | 25 (51.0) | 24 (49.0) | 1.01 (0.73–1.42) | ||||
| Number of people in the household | 424 | 3 (2–4) | 2 (2–4) | 0.92 (0.85–0.99) | 0.02 | 0.94 (0.85–1.04) | 0.2532 |
| RT-PCR SARS-CoV-2 Ct, per additional 10 unit | 260 | 24.8 (20.6–32.5) | 25.9 (21.1–31.6) | 0.87 (0.71–1.06) | 0.1657 | 0.78 (0.62–0.96) | 0.0201 |
| Time from symptom onset to RT-PCR test | 411 | 4 (1–7) | 3 (1–5) | 0.97 (0.95–0.99) | 0.0112 | 0.96 (0.93–0.99) | 0.0161 |
| Number of symptoms at inclusion | 429 | 4 (3–6) | 4 (3–6) | 0.95 (0.90–1.00) | 0.0607 | 0.98 (0.91–1.05) | 0.5046 |
| Diarrhea | 429 | ||||||
| No | 140 (39.9) | 211 (60.1) | 1 | 0.6502 | |||
| Yes | 35 (44.9) | 43 (55.1) | 0.94 (0.71–1.24) | ||||
| Myalgia | 429 | ||||||
| No | 77 (40.1) | 115 (59.9) | 1 | 0.8001 | |||
| Yes | 98 (41.4) | 139 (58.6) | 1.03 (0.83–1.28) | ||||
| Asthenia | 429 | ||||||
| No | 95 (39.8) | 144 (60.2) | 1 | 0.2749 | |||
| Yes | 80 (42.1) | 110 (57.9) | 0.89 (0.72–1.10) | ||||
| Fever | 429 | ||||||
| No | 82 (42.5) | 111 (57.5) | 1 | 0.2768 | |||
| Yes | 93 (39.4) | 143 (60.6) | 1.13 (0.91–1.40) | ||||
| Cough | 429 | ||||||
| No | 69 (37.9) | 113 (62.1) | 1 | 0.5786 | |||
| Yes | 106 (42.9) | 141 (57.1) | 0.94 (0.76–1.17) | ||||
| Rhinorrhea | 429 | ||||||
| No | 125 (42.1) | 172 (57.9) | 1 | 0.9524 | |||
| Yes | 50 (37.9) | 82 (62.1) | 0.99 (0.79–1.25) | ||||
| Headaches | 429 | ||||||
| No | 89 (44.7) | 110 (55.3) | 1 | 0.7725 | |||
| Yes | 86 (37.4) | 144 (62.6) | 1.03 (0.83–1.28) | ||||
| Anosmia | 429 | ||||||
| No | 103 (38.7) | 163 (61.3) | 1 | 0.1658 | 1 | 0.9294 | |
| Yes | 72 (44.2) | 91 (55.8) | 0.86 (0.69–1.07) | 1.02 (0.66–1.59) | |||
| Ageusia | 429 | ||||||
| No | 104 (38.2) | 168 (61.8) | 1 | 0.09 | 1 | 0.0248 | |
| Yes | 71 (45.2) | 86 (54.8) | 0.82 (0.66–1.03) | 0.59 (0.37–0.94) | |||
| Dyspnea | 429 | ||||||
| No | 149 (40.2) | 222 (59.8) | 1 | 0.4923 | |||
| Yes | 26 (44.8) | 32 (55.2) | 0.89 (0.65–1.23) | ||||
HR: hazard ratio; Cox proportional hazard model was used to assess factors associated with symptom persistence.
a
Inclusions started on March 10, 2020 and the last follow-up visit was on July 3, 2020.